MedPath

BRIDION

These highlights do not include all the information needed to use BRIDION safely and effectively. See full prescribing information for BRIDION. BRIDION (sugammadex) Injection, for intravenous use Initial U.S. Approval: 2015

Approved
Approval ID

5171d883-fe8f-482c-97ab-40b00975b64a

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 1, 2023

Manufacturers
FDA

Merck Sharp & Dohme LLC

DUNS: 118446553

Products 2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

sugammadex

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code0006-5423
Application NumberNDA022225
Product Classification
M
Marketing Category
C73594
G
Generic Name
sugammadex
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateNovember 17, 2022
FDA Product Classification

INGREDIENTS (4)

SUGAMMADEX SODIUMActive
Quantity: 100 mg in 1 mL
Code: ERJ6X2MXV7
Classification: ACTIM
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT

sugammadex

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code0006-5425
Application NumberNDA022225
Product Classification
M
Marketing Category
C73594
G
Generic Name
sugammadex
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateNovember 17, 2022
FDA Product Classification

INGREDIENTS (4)

SUGAMMADEX SODIUMActive
Quantity: 100 mg in 1 mL
Code: ERJ6X2MXV7
Classification: ACTIM
HYDROCHLORIC ACIDInactive
Code: QTT17582CB
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.